Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Boston Scientific granted European approval for cardiac device
According to the company, Acuity Spiral lead is seventh US or European regulatory approval in the past nine weeks. The Acuity Spiral lead is pending approval by the
According to the company, Acuity Spiral lead is seventh US or European regulatory approval in the past nine weeks. The Acuity Spiral lead is pending approval by the
Beta-bsm and Gamma-bsm are extensions to company’s unique line of bone substitute material products and provide the surgeon the flexibility to adapt to specific patient needs. Beta- bsm
The first allowed patent application is related to two clustered human hairpins and their related microRNAs. The second allowed patent application is related to microRNA US5-1, a viral
The trial was designed to evaluate safety, distribution and dosimetry of CardioPET as a PET tracer for myocardial imaging in healthy subjects and patients with coronary artery disease
The 111 study is a 12-week, Phase I, double-blind, parallel group, exploratory trial, where approximately 120 patients will be enrolled at around 30 clinical sites in the US.
The priority review designation means FDA is expected to make a decision on the NDA for the investigational compound within six months of the submission. If approved, Promacta
The companies will leverage Adept’s leadership in advanced image-guided robotic products and Prosurgics’s depth of experience in image-guided and navigated surgical robotic systems to create innovative products to
The transaction, which extends Gentiva’s home health operations to 37 states, has been funded from a combination of Gentiva’s existing cash balances and borrowings from its revolving credit
Under the terms of the agreement Neurobiological Technologies will exclusively license certain patent rights related to a naturally occurring protein that has been shown in animals to reverse
This randomized, double-blind, placebo and active-controlled, parallel-group study is designed to evaluate the compound’s safety and efficacy at three different doses in subjects with Stage I and Stage